This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a multi-centre, randomised controlled trial (RCT) that was set in 12 European countries. The method of randomisation was not reported. The protocol specified a minimum follow-up of 18 months and the mean duration of follow-up was 29.4 months (range: 18.0 to 44.7). The authors did not report details of blinding or of the loss to followup. Full details of the clinical trial have been published elsewhere (Cleland et al. 2001 and 2005) .
Analysis of effectiveness
The analysis of effectiveness was based on all patients included in the study. The authors did not specify that the analysis was conducted on an intention to treat basis, but the type of intervention studied means that it is almost certain to have been. The primary health outcome was time to death from any cause or unplanned hospitalisation for a major cardiovascular event. The authors did not report in this paper whether the groups were shown to be comparable at analysis.
Effectiveness results
The discounted within-trial restricted mean length of survival (until death or censorship) was 1.92 years (interquartile range, IQR: 1.51 to 2.52) with medical therapy alone and 2.02 years (IQR: 1.62 to 2.53) with CRT and medical therapy.
The gain in survival with CRT was 0.10 (95% confidence interval, CI: -0.01 to 0.21).
A discount rate of 3.5% was used.
Clinical conclusions
The authors concluded that the addition of CRT to medical therapy increases the quantity of life.
Measure of benefits used in the economic analysis
The measure of health benefits used was the quality-adjusted life-years (QALYs). The patients in the study completed the EQ-5D, a generic valuation matrix at baseline and at 90 days post-randomisation. They also completed a diseasespecific quality of life questionnaire, the Minnesota Living with Heart Failure Questionnaire (MLWHF), at baseline, 90 days post-randomisation, 18 months post-randomisation and at the end of the study. The authors modelled the relationship between the change in MLWHF score and change in EQ-5D score in order to predict utility values at 18 months and at the end of the study. Utility values of zero were applied from time of death or censorship.
Direct costs
The study included the direct costs to the health service. The comprised the costs of implantation procedures and the type of implant, the costs of hospital inpatient stay according to ward type, the costs of outpatient, cardiologist and primary care visits, the length of stay in nursing or residential homes or in a rehabilitation centre, and the costs of cardiovascular medication. The resource quantities and the costs were reported separately. The implant costs were estimated from the average list price across the countries included in the study. Other unit costs were based on UK National Health Service reference costs and published drug pricing lists. Discounting was relevant and a rate of 3.5% per annum was used, in line with recommendations by the UK Treasury. The study reported the average costs. The price year was not stated but it may be assumed to be 2004/05.
